News coverage about Fortress Biotech (NASDAQ:FBIO) has trended somewhat positive on Monday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Fortress Biotech earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.193101638764 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

A number of analysts have recently weighed in on the stock. FBR & Co reissued a “buy” rating on shares of Fortress Biotech in a research report on Tuesday, July 4th. Zacks Investment Research downgraded shares of Fortress Biotech from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. HC Wainwright set a $11.00 price target on shares of Fortress Biotech and gave the stock a “buy” rating in a research report on Tuesday, July 11th. Rodman & Renshaw assumed coverage on shares of Fortress Biotech in a research report on Tuesday, July 11th. They set a “buy” rating and a $11.00 price target for the company. Finally, ValuEngine raised shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research report on Wednesday, June 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $9.67.

Shares of Fortress Biotech (FBIO) opened at 3.86 on Monday. Fortress Biotech has a 52-week low of $1.88 and a 52-week high of $5.07. The firm’s market cap is $194.79 million. The stock’s 50 day moving average is $4.53 and its 200-day moving average is $3.76.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Fortress Biotech (FBIO) Share Price” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/14/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-fortress-biotech-fbio-share-price.html.

Fortress Biotech Company Profile

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Insider Buying and Selling by Quarter for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.